Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov
Abstract Background There are several challenges in designing clinical trials for the treatment of novel infectious diseases, such as COVID-19. In particular, the definition of endpoints related to the severity, time frame, and clinical course remains unclear. Therefore, we conducted a cross-section...
Guardado en:
Autores principales: | Kentaro Sakamaki, Yukari Uemura, Yosuke Shimizu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/18ac7fa14e8c498cb9fa73e033015f7a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Trends in patient‐reported outcome use in early phase dose‐finding oncology trials – an analysis of ClinicalTrials.gov
por: Julia Lai‐Kwon, et al.
Publicado: (2021) -
Overview of Clinical Trials on Type 2 Diabetes Mellitus: A Comprehensive Analysis of the ClinicalTrials.gov Database
por: Long J, et al.
Publicado: (2021) -
Obstacles to the reuse of study metadata in ClinicalTrials.gov
por: Laura Miron, et al.
Publicado: (2020) -
Evaluating the frequency of English language requirements in clinical trial eligibility criteria: A systematic analysis using ClinicalTrials.gov.
por: Akila V Muthukumar, et al.
Publicado: (2021) -
Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis
por: Yanhong Yao, et al.
Publicado: (2021)